HHLR Advisors’s Passage Bio PASG Stock Holding History

HHLR Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,531	Closed	-$3.29M	–	103
2020 Q3	$3.29M	Hold	12,531	–	–	0.02%	83
2020 Q2	$6.85M	Hold	12,531	–	–	0.06%	60
2020 Q1	$3.95M	Buy	+12,531	New	+$3.92M	0.05%	54

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HHLR Advisors's PASG Position: Q4 2020 in Review

HHLR Advisors sold out of Passage Bio (PASG) in Q4 2020, closing a stake of 12,531 shares — an estimated $3.29M sold.

HHLR Advisors first reported a position in PASG in Q1 2020 and held it in 3 quarters. The position peaked at $6.85M in Q2 2020. 71 funds tracked by Wall St. Rank hold PASG as of Q4 2020.

HHLR Advisors reported no remaining Passage Bio position as of Q4 2020 after selling out during the quarter.
HHLR Advisors sold 12,531 Passage Bio shares in Q4 2020, an estimated $3.29M.
HHLR Advisors first reported a position in Passage Bio in Q1 2020 and held it in 3 quarters.
HHLR Advisors's Passage Bio position peaked at $6.85M in Q2 2020.
71 funds tracked by Wall St. Rank held Passage Bio as of Q4 2020.

Based on HHLR Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.